NCT00734851 - Multimodality Phase II Study in Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

September 30, 2014

Study Completion Date

November 30, 2014

Conditions

Prostate Cancer

Interventions

DRUG

Docetaxel

Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily

DRUG

Sunitinib

Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone

RADIATION

EBXRT

External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.

Trial Locations (3)

Johns Hopkins University, Baltimore

Duke University, Durham

The Cancer Institute of New Jersey, New Brunswick